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Keywords: Background: There are limited studies on the relationship between inﬂammatory marker such as IL-6
Metabolic syndrome and lipid peroxidation and metabolic syndrome.
Lipid peroxidation Objective: The aim of present study was to assess IL-6 and lipid peroxidation in subjects with and
Interleukin-6 without the metabolic syndrome and their association with metabolic syndrome
Gorgan
 components.
Methods: Age and gender matched 40 subjects with metabolic syndrome and 40 control groups took
part in this study.
Results: The mean malondialdehyde level was signiﬁcantly higher in overweight and obese subjects
with metabolic syndrome than control groups (P < 0.05). The mean level of IL-6 in men and the mean
level of malondialdehyde in women with metabolic syndrome was signiﬁcantly higher than control
groups (p < 0.05). There were signiﬁcant positive correlation between malondialdehyde and fasting
blood glucose, triglyceride and systolic blood pressure (p < 0.05).
Conclusions: Our results suggest that higher levels of IL-6 and malondialdehyde may cause insulin
resistance and metabolic disorders in all subjects with metabolic syndrome. Malondialdehyde level
shows strong association with some metabolic syndrome components. This means the greater risk of
metabolic syndrome.
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Metabolic syndrome (MS) is known as an important risk factor
for cardiovascular disease and type II diabetes [1]. It is reported
recently that the prevalence of the metabolic syndrome in U.S.
adults above20 years old was almost 23.7% [2,3]. Marjani et al.
showed that metabolic syndrome and lipid peroxidation alter in
different ethnic and age groups, postmenopausal women and
different diseases [4–15]. Oxidative stress occurs when there is
instability between tissue, free radicals, and reactive oxygen
species and antioxidants system. This instability causes oxidative
damage [16]. Oxidative stress shows an important role in the* Corresponding author at: Metabolic Disorders Research Center, Department of
Biochemistry and Biophysics, Gorgan of Faculty of Medicine, Golestan University  
Medical Sciences,  Gorgan, Golestan province, Iran. Tel.: +98(171)4421651;
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1871-4021/ 2016 Published by Elsevier Ltd on behalf of Diabetes India.pathogenesis of different diseases [17]. Studies have indicated that
oxidative stress damage glucose uptake by muscle and fat cells
[18,19]. It also reduces insulin secretion from pancreatic b cells
[20]. Oxidative stress may be elevated by components of metabolic
syndrome such as insulin resistance, type II diabetes, hypertension,
dyslipidemia, visceral obesity [21–23], impaired vascular function,
inﬂammation, thrombosis, and atherosclerosis and vascular
disease [24]. These diseases may associate with metabolic
syndrome. Studies have revealed that elevated oxidative stress
and inﬂammatory stress play a signiﬁcant role in beginning and
development of atherosclerotic vascular disease [25,26]. It has
reported that low density lipoprotein oxidation as a marker of
oxidative stress increased in patients with coronary heart disease
[25] and subclinical atherosclerosis [27]. It has shown that the
metabolic syndrome reveals an association with elevated oxidative
stress and inﬂammatory burden [28,29]. The risk of coronary heart         
disease was more seen in obese subjects syndrome with metabolic 
when compared to  without subjects it [30]. IL-6 is a proinﬂam-
matory cytokine. Macrophages and smooth muscle cells secret it in
Table 1






Age (years) 48.50  7.80 46.20  9.70 0.227
BMI (kg/m2) 29.95  3.82 26.35  4.14 0.0001
Overweight
IL-6 (pg/ml) 3.74  0.24 3.50  0.01 0.342
Malondialdehyde (nmol/l) 3.40  0.20 1.90  0.19 0.02
Obese
IL-6 (pg/ml) 6.85  2.07 4.40  0.93 0.063
Malondialdehyde (nmol/l) 3.58  050 1.89  0.15 0.01
The p-value of tables is in bold.
Table 2








Number of subjects (%) 18 (100%) 18 (100%)
Age (years) 49.11  8.74 45.72  11.40 0.324
BMI (kg/m2) 30.88  3.53 25.98  2.34 0.0001
IL-6 (pg/ml) 7.14  0.24 3.50  0.01 0.0001
Malondialdehyde (nmol/l) 3.36  0.23 2.01  0.11 0.262
Women
Number of subjects (%) 22 (55%) 22 (55%)
Age (years) 48  7.11 46.59  6.86 0.507
BMI (kg/m2) 29.18  3.96 26.65  5.01 0.071
IL-6 (pg/ml) 3.77  0.21 3.92  0.42 0.351
Malondialdehyde (nmol/l) 3.65  0.45 1.75  0.14 0.001
The p-value of tables is in bold.
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blood cells (T cells and macrophages) and adipocytes [33–36]. It
has associated with obesity and some components of the metabolic
syndrome such as insulin resistance and dyslipidemia [37–39].
Studies have indicated that there is an association between
elevated risk of coronary heart disease [40–43] and type 2 diabetes
mellitus with IL-6. It has shown that IL-6 has principal role in the
relationship among inﬂammation, obesity and cardiovascular
disease [44]. Some other ﬁndings have shown that increased
interleukin (IL)-6 used as a marker of systemic inﬂammation and
diagnostic marker of future atherosclerotic events [45,46]. Clinical
studies showed that the level of interleukin-6 (IL-6) is used as
inﬂammatory marker for diagnosis of early stages of coronary
artery disease [47]. It is recently reported that low-grade
inﬂammation shows an important effect on the pathobiology of
metabolic syndrome [47,48]. There are limited studies on the
relationship between inﬂammatory marker such as IL-6 and lipid
peroxidation and metabolic syndrome. The aim of present study
was to assess IL-6 and lipid peroxidation in subjects with and
without the metabolic syndrome and their association with
metabolic syndrome components.
2. Methods
Age and gender matched 40 subjects with metabolic syndrome
and 40 control groups took part in this study. Blood samples were
collected after overnight fasting from all subjects who were
referred to the Jelleyin health center in Golestan University of
Medical Sciences, 2014. Commercial kit (With the use of
photometer techniques, Model CLINIC II-Photometer) were used
for determination of serum fasting glucose, triglycerides, LDL-
cholesterol and HDL-cholesterol levels in the Metabolic Disorders
Research Center, Gorgan Faculty of Medicine. Weight measure-
ment of all subjects was done, while subjects were minimally
clothed without shoes, using digital scales. Height measurement of
all subjects was carried out in standing position using tape meter
while the shoulder was in a normal position. Body mass index
(BMI) was calculated as weight in kilograms divided by height in
meters squared. Subjects with BMI = 25.0–29.9 kg/m2 and BMI
30 kg/m2 were indicated as overweight and obese subjects,
respectively [38]. Waist circumferences were determined at the
point halfway between the lower border of ribs and the iliac crest
in a horizontal plane [49]. Systolic and diastolic blood pressure was
measured in sitting position from the right hand. Subjects with 3 or
more of the below mentioned criteria were considered as a
metabolic syndrome subjects according to Adult Treatment Panel
III deﬁnition [50]:
A. Waist circumference >102 cm in men and >88 cm in women.
B. Serum triglycerides level 150 mg/dl.
C. Low HDL-cholesterol: <40 mg/dl in men and <50 mg/dl in
women.
D. Systolic blood pressure (SBP) 130 mmHg and/or diastolic
blood pressure (DBP) 85 mmHg or on treatment for hyper-
tension.
E. Serum glucose level 110 mg/dl or on treatment for diabetes.
Serum IL-6 (Picogram/ml) and malondialdehyde (Nano mol/l)
were determined by Immunoassay (LOT: IL6041453, REF:
EIL06001, Germany) and Kei Satoh (using spectrophotometer
technique, JENWAY6305) [51] methods, respectively ((the level of
lipid peroxidation expressed as Malondialdehyde (MDA)). Collect-
ed data was analyzed using SPSS–16 version software. Statistical
analysis of data expressed as percentage and means and standard
deviations. Chi squared, independent sample t and Pearson’scorrelation tests were used to evaluate data. Statistical differences
were considered signiﬁcant if p < 0.05.
3. Results
The clinical and biochemical data of the subjects with metabolic
syndrome and control group were shown in Table 1. The mean
malondialdehyde level was signiﬁcantly higher in overweight and
obese subjects with metabolic syndrome than control groups
(P < 0.05). Table 2 shows characteristic of the men and women
with metabolic syndrome and control groups. The mean level of
IL-6 in men and the mean level of malondialdehyde in women with
metabolic syndrome was signiﬁcantly higher than control groups
(p < 0.05). Correlation between metabolic syndrome components
and IL-6 and malondialdehyde are shown in Table 3. There were
signiﬁcant positive correlation between malondialdehyde and
fasting blood glucose, triglyceride and systolic blood pressure
(p < 0.05). There were no signiﬁcant correlation between IL-6 and
metabolic syndrome components. There were no signiﬁcant
correlation between IL-6 and malondialdehyde (P = 0.917, not
shown in result section).
4. Discussion
In present study, we observed that the levels of IL-6 were
signiﬁcantly higher in subjects with the metabolic syndrome
(Table 1). Studies have shown that there is an association between
the participation of IL-6 and systemic inﬂammatory responses that
causes to metabolic syndrome [52,53]. Higher levels of IL-6 in men
than in women show that abdominal obesity, which is more
prevalent in men, causes more proatherogenic cytokines produc-
tion. This may show that men are more in higher risk for
Table 3





R P-value r P-value
Glucose (mg/dl) 0.474 0.0001 0.007 0.948
Triglyceride (mg/dl) 0.224 0.003 0.065 0.565
HDL-C (mg/dl) 0.064 0.573 0.131 0.247
Waist circumference (cm) 0.388 0.0001 0.193 0.256
Systolic blood pressure 0.232 0.038 0.126 0.256
Diastolic blood pressure 0.151 0.183 0.054 0.637
The p-value of tables is in bold.
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levels than women which is not in agreement with some other
studies [52,55]. IL-6, as a pro-inﬂammatory cytokine was higher in
obese subjects than overweight subjects with metabolic syn-
drome. This may shows a relationship between obesity and IL-6
levels [56]. Some studies have indicated that serum IL-6 were not
associated with metabolic syndrome [57,58]. It revealed that IL-6
has an important role in development of insulin resistance [44,59]
while some other studies reported IL-6 prevents insulin resistance
[60]. Our results showed that there were no signiﬁcant correlation
between IL-6 and metabolic syndrome components. Thus, in
contrast to some other studies, it may suggest that IL6 could not be
used as a biomarker for the diagnosis of metabolic syndrome
[57]. Oxidative stress may play a signiﬁcant role in the develop-
ment of metabolic syndrome [23]. In the present study mal-
ondialdehyde level was statistically signiﬁcant in subjects with
metabolic syndrome which was not in agreement with some
studies [61,62] while it was in agreement with some other ﬁndings
[16]. The results of this study show that the metabolic syndrome
intensiﬁes oxidative stress in subjects with metabolic syndrome.
The present study also shows that oxidative stress was signiﬁ-
cantly higher in overweight and obese subjects with metabolic
syndrome in comparison with subjects without metabolic
syndrome which is in agreement with the ﬁndings of other
studies that they have shown independent association of obesity
and metabolic syndrome with elevated oxidative stress and
inﬂammatory burden [28,29,45,46]. In the present study, we also
determined the correlations between oxidative stress and meta-
bolic syndrome components. Our ﬁndings showed that the
oxidative stress was signiﬁcantly positive correlated with triglyc-
eride, glucose, systolic blood pressure and waist circumference in
our study subjects (Table 3). It can be suggest that subjects with
metabolic syndrome may have a higher level of oxidative stress. In
general, abdominal obesity has seen in subjects with metabolic
syndrome. Obesity makes happen oxidative stress that may cause
to the decrease of antioxidant enzymes activities [63]. This may
inﬂuence on inﬂammation which plays a pathogenic role in the
development and progression of metabolic syndrome [64].
5. Conclusion
Our results suggest that higher levels of IL-6 and malondialde-
hyde may cause insulin resistance and metabolic disorders in all
subjects with metabolic syndrome. Malondialdehyde level shows
strong association with some metabolic syndrome components.
This means the greater risk of metabolic syndrome.
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